

Jesús-José Ferre-Fernández

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6946453/publications.pdf>

Version: 2024-02-01

11
papers

132
citations

1163117

8
h-index

1372567

10
g-index

13
all docs

13
docs citations

13
times ranked

203
citing authors

#	ARTICLE	IF	CITATIONS
1	Knockout of myoc Provides Evidence for the Role of Myocilin in Zebrafish Sex Determination Associated with Wnt Signalling Downregulation. <i>Biology</i> , 2021, 10, 98.	2.8	2
2	Disruption of foxc1 genes in zebrafish results in dosage-dependent phenotypes overlapping Axenfeld-Rieger syndrome. <i>Human Molecular Genetics</i> , 2020, 29, 2723-2735.	2.9	15
3	Apparent Radiological Improvement in an Infant With Labrune Syndrome Treated With Bevacizumab. <i>Pediatric Neurology</i> , 2020, 112, 53-55.	2.1	7
4	Role of GUCA1C in Primary Congenital Glaucoma and in the Retina: Functional Evaluation in Zebrafish. <i>Genes</i> , 2020, 11, 550.	2.4	10
5	CPAMD8 loss-of-function underlies non-dominant congenital glaucoma with variable anterior segment dysgenesis and abnormal extracellular matrix. <i>Human Genetics</i> , 2020, 139, 1209-1231.	3.8	23
6	Role of FOXC2 and PITX2 rare variants associated with mild functional alterations as modifier factors in congenital glaucoma. <i>PLoS ONE</i> , 2019, 14, e0211029.	2.5	10
7	Whole-Exome Sequencing of Congenital Glaucoma Patients Reveals Hypermorphic Variants in GPATCH3, a New Gene Involved in Ocular and Craniofacial Development. <i>Scientific Reports</i> , 2017, 7, 46175.	3.3	22
8	Functional characterization of eight rare missense CYP1B1 variants involved in congenital glaucoma and their association with null genotypes. <i>Acta Ophthalmologica</i> , 2016, 94, e555-e560.	1.1	8
9	The Role of hsa-miR-548l Dysregulation as a Putative Modifier Factor for Glaucoma-Associated FOXC1 Mutations. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , 2015, 4, 50-56.	1.2	8
10	Hypo- and Hypermorphic FOXC1 Mutations in Dominant Glaucoma: Transactivation and Phenotypic Variability. <i>PLoS ONE</i> , 2015, 10, e0119272.	2.5	24
11	C-Terminal-PEDF Reduces IC50 Doses and Chemoresistant Population of CD133 and BCRP1-Positive Cancer Stem Like Cells. <i>Journal of Analytical Oncology</i> , 0, , .	0.1	2